Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
04
07
2018
revised:
19
10
2018
accepted:
05
11
2018
pubmed:
11
11
2018
medline:
18
12
2019
entrez:
11
11
2018
Statut:
ppublish
Résumé
To explore the practice and attitudes of uro-oncologists in the UK regarding monitoring testosterone levels and the use of testosterone replacement therapy (TRT) in their prostate cancer patients treated with androgen deprivation therapy (ADT). An expert-devised online questionnaire was completed by the members of the British Uro-oncology Group (BUG). Of 160 uro-oncologists invited, 84 completed the questionnaire. Before initiating ADT in patients with non-metastatic prostate cancer, only 45% of respondents measured testosterone levels and 61% did not measure testosterone at all during ADT in the adjuvant or neoadjuvant setting. However, in men with metastatic prostate cancer, 71% of the uro-oncologists measured testosterone before starting ADT and the majority continued testing during treatment. Approximately two-thirds of respondents did not prescribe TRT for their patients who were in remission following neo(adjuvant) ADT and who had castration levels of testosterone. Among UK uro-oncologists, the measurement of testosterone levels before and during ADT was not typically part of routine practice in the management of patients with prostate cancer. However, testosterone levels were checked more frequently for patients with metastatic disease than disease at an earlier stage. Testing could be conducted in parallel with PSA measurement as testosterone levels are linked to biochemical failure. The majority of specialists participating in the survey did not prescribe TRT for their patients in remission following ADT. Uro-oncologists in the UK do not generally measure testosterone as part of their patient management and they remain cautious about the possible benefits of TRT in men with prostate cancer.
Substances chimiques
Androgen Antagonists
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-6Subventions
Organisme : Ferring Pharmaceuticals
Informations de copyright
© 2018 John Wiley & Sons Ltd.
Références
Basaria S. Male hypogonadism. Lancet. 2014;383:1250-1263.
Wu F, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-135.
Traish AM, Abdou A, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol. 2009;51:303-313.
Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl. 2009;30:23-32.
Mouser JG, Loprinzi PD, Loenneke JP. The association between physiologic testosterone levels, lean mass, and fat mass in a nationally representative sample of men in the United States. Steroids. 2016;115:62-66.
Deijen JB, de Boer H, Blok GJ, van der Veen EA. Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology. 1996;21:313-322.
Dohle GR, Arver S, Bettocchi C, et al. Guidelines on male hypogonadism. Arnhem, The Netherlands: European Association of Urology; 2015.
Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos B, et al. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2018;103:1745-1754.
Guo C, Gu W, Liu M, et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: a meta-analysis study of placebo-controlled trials. Exp Ther Med. 2016;11:853-863.
Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and meta-analysis. BMJ Open. 2017;7:e015284. https://doi.org/10.1136/bmjopen-2016-015284
Nian Y, Ding M, Hu S, et al. Testosterone replacement therapy improves health-related quality of life for patients with late-onset hypogonadism: a meta-analysis of randomized controlled trials. Andrologia. 2017;49:e12630. https://doi.org/10.1111/and.12630
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618-629.
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630-642.
Tombal B, Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl. 2008;7:15-21.
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix, a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531-1538.
Klotz L, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33:1151-1156.
Bertaglia V, Tucci M, Fiori C, et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer. 2013;11:325-330.
Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178:1290-1295.
Wilke D, Patil N, Hollenhorst H, Bowes D, Rutledge R, Ago C. Testosterone suppression with luteinizing hormone-releasing hormone (LHRH) agonists in patients receiving radiotherapy for prostate cancer. Pharmacotherapy. 2018;38:327-333.
White ID, Wilson J, Aslet P, et al. Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int J Clin Pract. 2015;69:106-123.
Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression therapy for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895-903.
Gulley JL, Aragon-Ching JB, Steinberg SM, et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen-deprivation therapy in nonmetastatic prostate cancer. J Urol. 2008;180:1432-1437.
Pickles T, Agranovich A, Berthelet E, et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer. 2002;94:362-367.
DiBlasio CJ, Malcolm JB, Derweesh IH, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int. 2008;102:39-43.
Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and analysis. Urol Oncol. 2017;35:664.e1-664.e9.
Bosco C, Crawley D, Adolfsson J, et al. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS ONE. 2015;10(3):e0117344.
Haseen F, Murray LJ, Cardwell CR, et al. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv. 2010;4:128-139.
Wang A, Obertova Z, Brown C, et al. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer. 2015;15:837.
Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800-805.
Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386-396.
Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32:335-346.
Smith MR, Edegerdie B, Hernandez-Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-755.
Poon Y, Pechlivanoglou P, Alibhai S, et al. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int. 2018;121:17-28.
Boyle P, Koechlin A, Bota M, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016;118:731-741.
Debryune F, Behre HM, Roehrborn CG, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017;119:216-224.
Kuhn CM, Strasser H, Romming A, et al. Testosterone replacement therapy in hypogonadal men following prostate cancer treatment: a questionnaire-based retrospective study among urologists in Bavaria, Germany. Urol Int. 2015;95:153-159.
Kaplan AL, Lenis AT, Shah A, et al. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med. 2015;12:374-380.
Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radiotherapy. J Urol. 2013;190:639-644.
Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165-1170.
Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536-541.
Leibowitz RL, Dorff TB, Tucker S, et al. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2010;105:1397-1401.
Kaplan AL, Hu JC, Morgentaler A, et al. Testosterone therapy in men with prostate cancer. Eur Urol. 2016;69:894-903.
Keizman D, Huang P, Antonarakis ES, et al. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen blockade. Prostate. 2011;71:1608-1615.
Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. Clinical Guideline 175. January 2014. Accessed April 2, 2018.
Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2018; https://doi.org/10.1038/s41391-018-0079-0